A Pilot Study of Autologous Ex Vivo Activated NK Cell Infusion in the Treatment of Metastatic Nasopharyngeal Carcinoma
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
1. To demonstrate the feasibility of leukapheresis and ex vivo activation of autologous NK
cells in patients with metastatic NPC
2. To demonstrate the safety of low dose systemic IL-2 in combination with escalating doses
of autologous Ex Vivo Activated NK cells in patients with metastatic NPC
3. To assess immune measurements such as quantitation of regulatory T cells, EBV specific T
cells, serum cytokine levels, and NK cell function after treatment with IL-2 and
autologous Ex Vivo Activated NK cells